China NMPA Drug Inspection - Tianjin Boai Biopharmaceutical Co., Ltd. - Pudilan Anti-inflammatory Tablets
China NMPA drug inspection for Tianjin Boai Biopharmaceutical Co., Ltd. published January 31, 2018. Drug: Pudilan Anti-inflammatory Tablets. The Shanghai Municipal Food and Drug Administration (SMFDA) released its 2018 First Quarter drug supervision and samplin
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
China NMPA drug inspection for Tianjin Boai Biopharmaceutical Co., Ltd. published January 31, 2018. Drug: Pudilan Anti-inflammatory Tablets. The Shanghai Municipal Food and Drug Administration (SMFDA) released its 2018 First Quarter drug supervision and samplin
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox